November 18, 2022 11:26 AM EST
Cell/Gene Tx
FDA+

FDA hits Io­vance with one more de­lay for TIL ther­a­py, ex­tend­ing BLA fil­ing un­til 2023

Amber Tong

Io­vance Bio­ther­a­peu­tics is once again push­ing back its fil­ing plans for its cell ther­a­py — the lat­est in a three-year streak of de­lays — al­though ex­ecs say …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times